Global Peptide CDMO Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global Peptide CDMO Market 2023 by Company, Regions, Type and Application, Forecast to 2029

According to our (Global Info Research) latest study, the global Peptide CDMO market size was valued at USD 3265.7 million in 2022 and is forecast to a readjusted size of USD 8327.1 million by 2029 with a CAGR of 14.3% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Global key peptide CDMO producers include Bachem, PolyPeptide, CordenPharma, and others. The top five manufacturers together account for 40% of the market share, with the largest manufacturer being Bachem with 17%. At the sales level, North America is the largest sales market with a market share of over 50%, followed by Europe and China with 33% and 9% respectively. In terms of product categories, it is divided into APIs and intermediates and FDF, with the former holding the major market share of 67%. In terms of application, commercial is the top application area with a market share of 76%, followed by academic research institutions.

Peptides are synthesized by coupling the carboxyl group of one amino acid to the amino group of another amino acid molecule. Due to the possibility of unintended reactions, protecting groups are common necessary. Chemical peptide synthesis most commonly starts at the carboxyl end of the peptide, and thus progress toward the amino-terminus. This is the opposite direction of protein biosynthesis.

A contract development and manufacturing company (CDMO) is a company within the pharmaceutical industry that provides drug development and manufacturing services. Pharmaceutical companies partner with CDMOs as a way to outsource drug development and drug manufacturing.

CDMO peptides production via contract peptide manufacturing is to optimize process development and achieve highly efficient conversion at every amino acid coupling to produce a high-purity crude synthetic custom peptide and minimize the demands on downstream processing.

This report is a detailed and comprehensive analysis for global Peptide CDMO market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Peptide CDMO market size and forecasts, in consumption value ($ Million), 2018-2029

Global Peptide CDMO market size and forecasts by region and country, in consumption value ($ Million), 2018-2029

Global Peptide CDMO market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029

Global Peptide CDMO market shares of main players, in revenue ($ Million), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Peptide CDMO

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Peptide CDMO market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bachem, PolyPeptide, CordenPharma, AmbioPharm and USV Peptides, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation

Peptide CDMO market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
APIs and Intermediates
FDF

Market segment by Application
Commercial
Academic Research
Other

Market segment by players, this report covers
Bachem
PolyPeptide
CordenPharma
AmbioPharm
USV Peptides
Thermofischer
Bio Basic
JPT
Genscript
Xinbang Pharma
ScinoPharm
SN Biopharm
CBL
Piramal Pharma
CPC Scientific

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Peptide CDMO product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Peptide CDMO, with revenue, gross margin and global market share of Peptide CDMO from 2018 to 2023.

Chapter 3, the Peptide CDMO competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Peptide CDMO market forecast, by regions, type and application, with consumption value, from 2024 to 2029.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War

Chapter 12, the key raw materials and key suppliers, and industry chain of Peptide CDMO.

Chapter 13, to describe Peptide CDMO research findings and conclusion.